title: Allogeneic hematopoietic stem cell transplantation for advanced extranodal natural killer/T-cell lymphoma, nasal type.
abstract: The prognosis for patients with advanced or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL) is extremely poor. Thus, allogeneic stem cell transplantation (allo-HSCT) should be considered for this disease. However, reports of allo-HSCT for ENKL are limited because of the rarity of the disease. Here, we describe the clinical course of 12 cases of advanced and refractory ENKL treated with allo-HSCT, including five cases with cord blood transplant. With a median follow-up of 13 months (range, 1-168 months), seven patients are alive in remission, five have died, and one treatment-related death occurred. All patients with disease progression at transplant died of disease progression, whereas seven of eight patients with a complete or partial response are long-term survivors. Allo-HSCT is a feasible and promising consolidation therapy for advanced and relapsed ENKL. The disease status before allo-HSCT is well associated with general outcome, and thus induction treatment is very important for this disease.
authors: Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. daisukeennishi@yahoo.co.jp
authors: Daisuke
authors: D
authors: Ennishi
authors: Yoshinobu
authors: Y
authors: Maeda
authors: Nobuharu
authors: N
authors: Fujii
authors: Eisei
authors: E
authors: Kondo
authors: Katsuji
authors: K
authors: Shinagawa
authors: Kazuma
authors: K
authors: Ikeda
authors: Koichi
authors: K
authors: Ichimura
authors: Tadashi
authors: T
authors: Yoshino
authors: Mitsune
authors: M
authors: Tanimoto